A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide

What Was Tested

In this phase 1 trial, researchers set out to test Semaglutide.

This will be a phase I, randomized, double-blind, placebo-controlled.

This study will be conducted in three periods: the screening period, the treatment period, and the follow-up period.

It had three arms (groups): Combo Cohort 1 in participants with obesity (experimental), Combo Cohort 2 in participants with obesity (experimental) and Combo Cohort 3 in participants with obesity (experimental).

The registry classes the interventions as drug.

Who Took Part

The registry lists 28 actual participants took part.

It was open to people of any sex aged from 18 years up to 65 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Subject have provided informed consent before initiation of any study specific procedures.

The full record lists 4 inclusion and 5 exclusion criteria; among the exclusions: have a positive alcohol or drug screen at screening or have a history of alcohol or drug abuse within the past 1 year; have an autoimmune disease, is immunosuppressed or is in any way immunocompromised.

How the Study Was Run

The set-up was randomized, sequential and triple-blind.

The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Semaglutide.

Those kept unaware of assignments: participant, care provider and investigator.

It started in 2025-04-18 with completion listed for 2025-09-22.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Adverse events (time frame: up to 71 days).

It also tracked 5 secondary outcomes, for example Change From Baseline in Body Weight, Cmax of ASC47, AUC of ASC47, T1/2 of ASC47 and CL/F of ASC47.

What This Means in Plain Language

Put simply, this is a phase 1, randomized trial of Semaglutide in 28 people.

Its size is small, so on its own it can only give an early look.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.